When trials are done in the name of brain cancer, it's clear that some will be noticed more than others. Very rarely have I ever tuned into a story of this nature to learn that the process is only going to take a day's time. This is a process that calls for attention to detail, so how much detail can be picked up on in such a limited amount of time, you may wonder? It's good to see that certain procedures are set in place, which is the case for the ETS2101 trial.
According to the Wall Street Journal, the ETS2101 trial is one which includes a number of patients, each of them possessing a form of primary or secondary brain cancer. It was done in order to see the effect of ETS2101 and whether or not it is going to be for the best in the long term. As you can imagine, every patient was given a certain dosage so that it can be examined how their bodies take to it. It's been said that this study will continue on through 2014 and I think that organizations such as Voices against Brain Cancer should make note of it.
For those who are unfamiliar with ETS2101, what exactly is it, you may wonder? The article said that this is a drug which has been utilized in the past in order to study trauma patients. However, instances of pharmacology have shown that this drug may actually prove useful in the way of cancer as well. With two ongoing studies being done - one for primary cancer patients and the other for secondary cancer patients - there has been a great deal of time that's been invested with this study.
Back to the subject of the procedure, though, patients have been treated with gradually higher doses of the drug until a tolerated level has been found. The report said that fifteen patients have completed the study with doses relative to body waste and the results have been generally positive. They took to the ETS2101 drug well and tumors have not responded objectively to the drug in question. It's an instance of success that, in my opinion, can most likely lead to further results seen down the road.
It's clear that studies of this nature require time in order for them to be as effective as possible. Brain cancer, as one can imagine, is a serious condition and it deserves to be focused on consistently. The story regarding the usage of the ETS2101 drug is a strong one and it seems as though there have been results which can come into play later on. My only hope is that there are greater results which can then become even greater as more time - in addition to attention - is given.
According to the Wall Street Journal, the ETS2101 trial is one which includes a number of patients, each of them possessing a form of primary or secondary brain cancer. It was done in order to see the effect of ETS2101 and whether or not it is going to be for the best in the long term. As you can imagine, every patient was given a certain dosage so that it can be examined how their bodies take to it. It's been said that this study will continue on through 2014 and I think that organizations such as Voices against Brain Cancer should make note of it.
For those who are unfamiliar with ETS2101, what exactly is it, you may wonder? The article said that this is a drug which has been utilized in the past in order to study trauma patients. However, instances of pharmacology have shown that this drug may actually prove useful in the way of cancer as well. With two ongoing studies being done - one for primary cancer patients and the other for secondary cancer patients - there has been a great deal of time that's been invested with this study.
Back to the subject of the procedure, though, patients have been treated with gradually higher doses of the drug until a tolerated level has been found. The report said that fifteen patients have completed the study with doses relative to body waste and the results have been generally positive. They took to the ETS2101 drug well and tumors have not responded objectively to the drug in question. It's an instance of success that, in my opinion, can most likely lead to further results seen down the road.
It's clear that studies of this nature require time in order for them to be as effective as possible. Brain cancer, as one can imagine, is a serious condition and it deserves to be focused on consistently. The story regarding the usage of the ETS2101 drug is a strong one and it seems as though there have been results which can come into play later on. My only hope is that there are greater results which can then become even greater as more time - in addition to attention - is given.
About the Author:
Contact Voices Against Brain Cancer if you're searching for some more information about glioblastoma and brain cancer awareness.
Aucun commentaire:
Enregistrer un commentaire